MGNX - MacroGenics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

113.8M

Cash

241.7M

Avg Qtr Burn

-10.52M

Short % of Float

9.42%

Insider Ownership

2.69%

Institutional Own.

93.19%

Qtr Updated

03/31/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ZYNYZ (Retifanlimab) (anti-PD-1 mAb) Details Solid tumor/s, Cancer, Metastatic merkel cell carcinoma, Skin cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MARGENZA (Margetuximab) (Fc-engineered, anti-HER2 mAb) Details HER2-positive metastatic breast cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Retifanlimab (anti-PD-1 mAb) Details NSCLC (Non-small cell lung carcinoma) or Anal Cancer	NDA FDA meeting	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vobramitamab duocarmazine (vobra duo) (MGC018) Details Solid tumor/s, Cancer, Castration-resistant prostate cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Enoblituzumab (anti-B7-H3) Details Head and neck squamous cell carcinoma, Cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lorigerlimab (PD-1 × CTLA-4 bispecific DART® molecule) + docetaxel Details Solid tumor/s, Cancer, Castration-resistant prostate cancer	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vobramitamab duocarmazine combo w/lorigerlimab (PD-1 × CTLA-4 bispecific DART® molecule) Details Solid tumor/s, Non-small cell lung carcinoma, Cancer, Triple-negative breast cancer , Head and neck squamous cell carcinoma, Melanoma, Castration-resistant prostate cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MGD024 Details Myelodysplastic syndrome, Acute myeloid leukemia	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Margetuximab (Fc-engineered, anti-HER2 mAb) Details Gastric cancer, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Flotetuzumab (bispecific CD123 × CD3 DART molecule) Details Cancer, Multiple myeloma, Acute myeloid leukemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.